Targeting integrins in malignant glioma.

Détails

Ressource 1Télécharger: REF.pdf (143.66 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_91F72FFCA0A0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Targeting integrins in malignant glioma.
Périodique
Targeted Oncology
Auteur⸱e⸱s
Tabatabai G., Weller M., Nabors B., Picard M., Reardon D., Mikkelsen T., Ruegg C., Stupp R.
ISSN
1776-260X (Electronic)
ISSN-L
1776-2596
Statut éditorial
Publié
Date de publication
2010
Volume
5
Numéro
3
Pages
175-181
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.
Mots-clé
Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/metabolism, Clinical Trials as Topic, Glioma/drug therapy, Glioma/metabolism, Humans, Integrins/antagonists & inhibitors, Signal Transduction
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/10/2010 15:19
Dernière modification de la notice
14/02/2022 7:56
Données d'usage